---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-26-000025"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2026-04-03T23:59:59+00:00"
generated_at: "2026-05-15T07:39:19.820240+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma gets second NYSE American delisting notice over $55M equity deficit

## Summary
- March 31, 2026 notice: not compliant with Section 1003(a)(ii) requiring ≥$4M stockholders' equity.
- Stockholders' deficit ~$55M as of Dec 31, 2025; losses in 3 of last 4 fiscal years.
- Prior non-compliance (Section 1003(a)(i)) from Feb 2025; NYSE American accepted compliance plan through Aug 3, 2026.
- Stock continues trading under AEON with '.BC' indicator; company remains on noncompliant issuers list.
- Failure to regain compliance by Aug 3, 2026 could lead to delisting; business operations unaffected.

## SEC filing metadata
- accession: 0001837607-26-000025
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2026-04-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000025/0001837607-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000025/aeon-20260331x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-26-000025
- JSON: https://secwatch.observer/filing/0001837607-26-000025.json
- Plain text: https://secwatch.observer/filing/0001837607-26-000025.txt

## Source-grounded claims
- claim_id: 6212fff02e8d5bac8f5213fcc713a6fc6af15a5e
  claim: AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(ii)).
  evidence_excerpt: March 31, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) received an additional written notice of non-compliance (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(ii) requires stockholders’ equity of $4.0 million or more if a listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reporte
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000025/0001837607-26-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.